Ziconotide Dosage

This dosage information may not include all the information needed to use Ziconotide safely and effectively. See additional information for Ziconotide.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Geriatric Dose for:

Additional dosage information:

Usual Adult Dose for Pain

Initial dose: No more than 2.4 mcg per day (0.1 mcg/hour) by intrathecal (IT) administration

The dosage should be titrated to patient response. Doses may be titrated upward by up to 2.4 mcg/day (0.1 mcg/hour) at intervals of no more than 2 to 3 times per week, up to a recommended maximum of 19.2 mcg/day (0.8 mcg/hour) by day 21. Dose increases in increments of less than 2.4 mcg/day (0.1 mcg/hour) and increases in dose less frequently than 2 to 3 times per week may be used. The average dose level at the end of a 21 day clinical study was 6.9 mcg per day (0.29 mcg/hour).

Usual Geriatric Dose for Pain

The dose selection for elderly patients should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, and cardiac function, and of concomitant diseases or other drug therapy.

Initial dose: No more than 2.4 mcg per day (0.1 mcg/hour) by intrathecal (IT) administration

The dosage should be titrated to patient response. Doses may be titrated upward by up to 2.4 mcg/day (0.1 mcg/hour) at intervals of no more than 2 to 3 times per week, up to a recommended maximum of 19.2 mcg/day (0.8 mcg/hour) by day 21. Dose increases in increments of less than 2.4 mcg/day (0.1 mcg/hour) and increases in dose less frequently than 2 to 3 times per week may be used. The average dose level at the end of a 21 day clinical study was 6.9 mcg per day (0.29 mcg/hour).

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

The dose of ziconotide should be adjusted according to the severity of pain, response to therapy, and the occurrence of adverse events. The effective dose of ziconotide for analgesia is variable.

The dose of ziconotide should be reduced or discontinued if signs or symptoms of cognitive impairment develop, but other contributing causes should also be considered.

No rebound or other adverse events related to discontinuation of ziconotide have been reported in clinical trials.

Precautions

Because of the lower incidence of serious adverse events and discontinuations for adverse events associated with the slower titration, a faster titration schedule should only be used if there is an urgent need for analgesia that outweighs the risk to patient safety.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Dialysis

Data not available

Hide
(web5)